|

VRD for first-cycle induction therapy Clinical Trials

1 actively recruiting trial

Also known as: Bortezomib(V), Lenalidomide(R), Dexamethasone(D)

Pipeline

Phase 4: 1

Top Sponsors

  • The First Affiliated Hospital of Soochow University1

Indications

  • MRD1
  • High Risk1
  • Newly Diagnosed1
  • Multiple Myeloma1
  • Cancer1

Other1 trial

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.